ASX ANNOUNCEMENT – COMPLETION OF PRIVATE … · 2016-09-08 · Title: Microsoft Word - Osprey...

USOFFICE&HEADQUARTERS:Suite250|5600RowlandRoad|MinnetonkaMN55343|Tel:+1952.955.8230|Fax:+1952.955.8171|AUSTRALIANOFFICE:Level13,41ExhibitionStreet|MelbourneVIC3000|Tel:+61410442393|Fax:+61396636609|

AUSTRALIANPOSTALADDRESS:POBOX18355|CollinsStreetEast|MelbourneVIC8003OspreyMedicalInc.(ARBN152854923)isaforeigncompanyincorporatedinDelaware,USA.

www.ospreymed.com

ASXANNOUNCEMENT–COMPLETIONOFPRIVATEPLACEMENT

Minnesota, United States and Melbourne, Australia – 9 September 2016. OspreyMedical, Inc.(ASX:OSP)(OspreyorCompany)ispleasedtoannouncethat35,714,286CHESSDepositaryInterests(CDIs)(theequivalentof17,857,143sharesofCommonStock)havetodaybeenallottedtocompletetheissueofTranche2ofthePlacementannouncedon4August2016.

Theallocationtodaycompletesthe100MillionCDIallocationunderthePlacement.

AboutOsprey

OspreyMedicalisfocusedonprotectingpatientsfromtheharmfuleffectsofX-raydye(contrast)usedduringcommonlyperformedangiographicimagingprocedures.TheCompany’scoretechnologiesoriginatedfromresearchconductedbyDrDavid Kaye at Melbourne’s Baker IDI Heart and Diabetes Institute. Its proprietary dye reduction and monitoringtechnologiesaredesignedtohelpphysiciansminimizedyeusage.TheCompany’sDyeVert™Systemisanext-generationproduct that reduces contrast whilemaintaining image quality in a self-adjusting easy-to-use design. OspreyMedical’sBoardandManagementarecomprisedofexperiencedandsuccessfulpersonnelwithestablishedtrack recordscoveringmedical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’sadvisoryboardcomprisesworld-recognisedexpertsinheartandkidneydiseases.

Forward-LookingStatementsThis announcement contains or may contain forward-looking statements that are based on management’s beliefs,assumptions and expectations and on information currently available to management. All statements that addressoperatingperformance,eventsordevelopmentsthatweexpectoranticipatewilloccurinthefutureareforward-lookingstatements, including without limitation our expectations with respect to our ability to commercialize our productsincluding our estimates of potential revenues, costs, profitability and financial performance; our ability to develop andcommercializenewproductsincludingourabilitytoobtainreimbursementforourproducts;ourexpectationswithrespecttoourclinicaltrials, includingenrolment inorcompletionofourclinicaltrialsandourassociatedregulatorysubmissionsand approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.Management believes that these forward-looking statements are reasonable as andwhenmade. You should not placeundue reliance on forward-looking statements because they speak only as of the date when made. Osprey does notassume any obligation to publicly update or revise any forward-looking statements, whether as a result of newinformation,futureeventsorotherwise.Ospreymaynotactuallyachievetheplans,projectionsorexpectationsdisclosedinforward-lookingstatements,andactualresults,developmentsoreventscoulddiffermateriallyfromthosedisclosedintheforward-lookingstatements.

Media Investors Company

GavinLowerBuchanConsultingT:(613)88661215glower@buchanwe.com.au

RebeccaWilsonBuchanConsultingM:(61)417382391rwilson@buchanwe.com.au

DougSchoenbergVPofMarketingT:(952)9558230dschoenberg@ospreymed.com

For

per

sona

l use

onl

y